Valo Health’s diabetic retinopathy drug failed to improve patients' symptoms in a Phase 2 study, and the company is now on ...

Despite reporting a Phase 3 win this summer, Pfizer terminated its hemophilia A gene therapy pact with Sangamo Therapeutics ...